Read the Beforeitsnews.com story here. Advertise at Before It's News here.
Profile image
By IPO Scoop (Reporter)
Contributor profile | More stories
Story Views
Now:
Last hour:
Last 24 hours:
Total:

The IPO Buzz: BioAge Labs Upsizes IPO to Raise $189 Million – Up 40% – Before Pricing

% of readers think this story is Fact. Add your two cents.


BioAge Labs (BIOA Proposed), a Phase II biotech developing an anti-obesity drug, upsized its IPO early today by increasing the number of shares to 10.5 million – up from 7.5 million originally – according to an S-1/A filing dated Sept. 25, 2024. That’s a 40 percent increase. BioAge Labs now expects to raise $189 million – up from $135 million originally. The price range remained the same – at $17.00 to $19.00. The IPO’s proceeds will be used to finance clinical trials. BioAge Labs is expected to price its IPO  tonight –  Wednesday, Sept. 25, 2024 – to trade Thursday, Sept. 26, 2024 – on the NASDAQ. Goldman Sachs, Morgan Stanley, Jefferies and Citigroup are the joint book-runners. Under the new terms, the market cap for BioAge Labs would be $606. 01 million – up from $556.41 million under the original terms – assuming pricing at the $18.00 mid-point of its range. The Phase 2 biotech has a licensing agreement with Amgen, a material transfer agreement with Eli Lilly, and a commercial research funding agreement with Wellcome Leap, according to the prospectus.  The IPO was launched a week ago today – Wednesday, Sept. 18, 2024 – after BioAge Labs disclosed its initial terms in an S-1/A filing. BioAge Labs is evaluating its leading drug candidate, azelaprag, a pill, combined with an injectable GLP-1R agonist, in two Phase 2 clinical trials. GLP-1 agonists are glucagon-like peptide-1 agonists – a class of medications that includes Ozempic and Wegovy (semaglutide is the active ingredient) and Mounjaro and Zepbound (tirzepatide is the active ingredient) – used to treat Type 2 diabetes and obesity, according to the National Institutes of Health and WebMd. The BioAge Labs’ leading oral drug candidate, azelaprag, will be combined in Phase 2 clinical trials with either: –          An injection of tirzepatide,  marketed as Zepbound, Eli Lilly’s injectible drug to fight obesity; this is an ongoing STRIDES clinical trial with topline results anticipated in the third quarter of 2025, or –            –          An injection of semaglutide, marketed as Wegovy by Novo Nordisk; this Phase 2 trial is expected to begin in the first half of 2025 with topline results expected in the second half of 2026. “We believe these trials will directly support our ultimate therapeutic goal of developing an all-oral combination product for obesity,” BioAge Labs said in the prospectus.  BioAge Labs, founded in 2015, is based in the San Francisco suburb of Richmond, California. Principal shareholders include co-founder and CEO Kristen Fortney, who owns a 9.8 percent stake in BioAge Labs, and two of the top 15 U.S. venture capital firms –  Andreessen Horowitz owns – through various entities – a pre-IPO stake of 9.4 percent of the outstanding stock, while Khosla Ventures has a pre-IPO stake of 8 percent. BioAge Labs, like most clinical biotechs when they go public, has a history of net losses and no product revenue. BioAge Labs reported a net loss of $62.2 million on no product revenue for the 12 months that ended June 30, 2024, according to the prospectus.  (For more information about these companies, please check the IPO Calendar and the individual IPO Profiles found on IPOScoop.com’s website.) Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board. To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message. Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions. Disclaimer: A SCOOP Rating (Wall Street Consensus of Opening-day Premiums) is a general consensus taken, at press time, from Wall Street and investment professionals concerning how well an IPO might perform when it starts trading. The SCOOP Rating does not reflect the opinions or anyone associated with IPOScoop.com. The SCOOP ratings should not be taken as investment advice. The rating merely reflects the opinion of the professionals at the time of publication and is subject to last-minute changes due to market conditions, changes in a specific offering and other factors, such as changes in the proposed offering terms and the shifting of investor interest in the IPO. The information offered is taken from sources we believe to be reliable, but we cannot guarantee the accuracy.


Source: https://www.iposcoop.com/the-ipo-buzz-bioage-labs-upsizes-ipo-to-raise-189-million-up-40-before-pricing/



Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world.

Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.

"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.

Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world. Anyone can join. Anyone can contribute. Anyone can become informed about their world. "United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.


LION'S MANE PRODUCT


Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules


Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, but it benefits growth of Essential Gut Flora, further enhancing your Vitality.



Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity. Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins. Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system. Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome. Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function. Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.


Report abuse

    Comments

    Your Comments
    Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

    MOST RECENT
    Load more ...

    SignUp

    Login

    Newsletter

    Email this story
    Email this story

    If you really want to ban this commenter, please write down the reason:

    If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.